Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. / Andersen, G; Jensen, N H; Christrup, Lona Louring; Hansen, S H; Sjøgren, P.

In: Palliative Medicine, Vol. 16, No. 2, 03.2002, p. 107-14.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Andersen, G, Jensen, NH, Christrup, LL, Hansen, SH & Sjøgren, P 2002, 'Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine', Palliative Medicine, vol. 16, no. 2, pp. 107-14.

APA

Andersen, G., Jensen, N. H., Christrup, L. L., Hansen, S. H., & Sjøgren, P. (2002). Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliative Medicine, 16(2), 107-14.

Vancouver

Andersen G, Jensen NH, Christrup LL, Hansen SH, Sjøgren P. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliative Medicine. 2002 Mar;16(2):107-14.

Author

Andersen, G ; Jensen, N H ; Christrup, Lona Louring ; Hansen, S H ; Sjøgren, P. / Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. In: Palliative Medicine. 2002 ; Vol. 16, No. 2. pp. 107-14.

Bibtex

@article{8eff37b00e184604b5b1ca343623b8af,
title = "Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine",
abstract = "Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the two most important metabolites of morphine. Both are pharmacologically active, however, with different effects. M-6-G has been demonstrated capable of inducing anti-nociception and sedation, and M-3-G may induce behavioural excitation and possibly antagonise anti-nociception. Their impact on pharmacodynamics in patients in long-term treatment with oral morphine remains to be settled.",
keywords = "Adult, Aged, Analgesics, Opioid, Delayed-Action Preparations, Female, Humans, Male, Middle Aged, Morphine, Morphine Derivatives, Neoplasms, Pain",
author = "G Andersen and Jensen, {N H} and Christrup, {Lona Louring} and Hansen, {S H} and P Sj{\o}gren",
year = "2002",
month = mar,
language = "English",
volume = "16",
pages = "107--14",
journal = "Palliative Medicine",
issn = "0269-2163",
publisher = "SAGE Publications",
number = "2",

}

RIS

TY - JOUR

T1 - Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine

AU - Andersen, G

AU - Jensen, N H

AU - Christrup, Lona Louring

AU - Hansen, S H

AU - Sjøgren, P

PY - 2002/3

Y1 - 2002/3

N2 - Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the two most important metabolites of morphine. Both are pharmacologically active, however, with different effects. M-6-G has been demonstrated capable of inducing anti-nociception and sedation, and M-3-G may induce behavioural excitation and possibly antagonise anti-nociception. Their impact on pharmacodynamics in patients in long-term treatment with oral morphine remains to be settled.

AB - Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the two most important metabolites of morphine. Both are pharmacologically active, however, with different effects. M-6-G has been demonstrated capable of inducing anti-nociception and sedation, and M-3-G may induce behavioural excitation and possibly antagonise anti-nociception. Their impact on pharmacodynamics in patients in long-term treatment with oral morphine remains to be settled.

KW - Adult

KW - Aged

KW - Analgesics, Opioid

KW - Delayed-Action Preparations

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Morphine

KW - Morphine Derivatives

KW - Neoplasms

KW - Pain

M3 - Journal article

C2 - 11969141

VL - 16

SP - 107

EP - 114

JO - Palliative Medicine

JF - Palliative Medicine

SN - 0269-2163

IS - 2

ER -

ID: 46099227